Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population

NCT ID: NCT01877421

Last Updated: 2020-02-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 135 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-25
• Study Completion Date: 2016-03-31

Brief Summary

This study is to assess the safety and tolerability of single doses and multiple doses in reducing plaque and gingivitis when delivered in a chewing gum formulation.

Detailed Description

This study is a Phase 1/2a placebo-controlled, double-blind, randomized, dose-escalation study to evaluate the safety and proof of concept of Antiplaque Chewing Gum. This is a 2-part trial with 9 dosing cohorts in Phase 1 and 7 dosing cohorts in Phase 2a. For both phases, the oral soft (OST) and oral hard tissues (OHT) will be examined. Changes from baseline, such as soft tissue erythema, ulceration and sloughing, will be noted and assessments will be made by the principal investigator as to whether they might be attributable to the antiplaque chewing gum.

In the Phase 2a portion of the study, the efficacy of the antiplaque chewing gum in reducing existing supragingival plaque and gingivitis will also be assessed. Plaque will be assessed using the Turesky Modification of the Quigley-Hein Plaque Index (PI, Turesky et al-1970) and gingivitis will be assessed using both the Modified Gingival Index (MGI, Lobene et al-1986) and the percent of bleeding sites on gentle probing (BOP) using the methods described in Ainamo and Bay-1975.

Conditions

Plaque; Gingivitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

2 mg KSL-W (Phase 1, 1a)

one 2 mg KSL-W tablet at day 0 at Phase 1

Group Type: EXPERIMENTAL

2 mg KSL-W

Intervention Type: DRUG

4 mg KSL-W (Phase 1, 2a; Phase 2a, 1b)

one 4 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. one 4 mg KSL-W tablet on days 1-6; two 4 mg KSL-W tablets on days 7-13 and days 14-20; and three 4 mg tablets at days 21-27 at Phase 2a.

Group Type: EXPERIMENTAL

4 mg KSL-W

Intervention Type: DRUG

6 mg KSL-W (Phase 1, 3a; Phase 2a, 2b)

One 6 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 6 mg KSL-W tablet on days 1-6; two 6 mg KSL-W tablets on days 7-13 and days 14-20; and three 6 mg tablets at days 21-27 at Phase 2a.

Group Type: EXPERIMENTAL

6 mg KSL-W

Intervention Type: DRUG

10 mg KSL-W (Phase 1, 4a; Phase 2a, 3b)

One 10 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 10 mg KSL-W tablet on days 1-6; two 10 mg KSL-W tablets on days 7-13 and days 14-20; and three 10 mg tablets at days 21-27 at Phase 2a.

Group Type: EXPERIMENTAL

10 mg KSL-W

Intervention Type: DRUG

20 mg KSL-W (Phase 1, 5a; Phase 2a, 4b)

One 20 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 20 mg KSL-W tablet on days 1-6; two 20 mg KSL-W tablets on days 7-13 and days 14-20; and three 20 mg tablets at days 21-27 at Phase 2a.

Group Type: EXPERIMENTAL

20 mg KSL-W

Intervention Type: DRUG

30 mg KSL-W (Phase 1, 6a; Phase 2a, 5b)

One 30 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 30 mg KSL-W tablet on days 1-6; two 30 mg KSL-W tablets on days 7-13 and days 14-20; and three 30 mg tablets at days 21-27 at Phase 2a.

Group Type: EXPERIMENTAL

30 mg KSL-W

Intervention Type: DRUG

50 mg KSL-W (Phase 1, 7a; Phase 2a, 6b)

One 50 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 50 mg KSL-W tablet on days 1-6; two 50 mg KSL-W tablets on days 7-13 and days 14-20; and three 50 mg tablets at days 21-27 at Phase 2a.

Group Type: EXPERIMENTAL

50 mg KSL-W

Intervention Type: DRUG

75 mg KSL-W (Phase 1, 8a; Phase 2a, 7b)

One 75 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 75 mg KSL-W tablet on days 1-6; two 75 mg KSL-W tablets on days 7-13 and days 14-20; and three 75 mg tablets at days 21-27 at Phase 2a.

Group Type: EXPERIMENTAL

75 mg KSL-W

Intervention Type: DRUG

100 mg KSL-W (Phase 1, 9a)

one 100 mg KSL-W tablet at day 0 at Phase 1

Group Type: EXPERIMENTAL

100 mg KSL-W

Intervention Type: DRUG

Placebo

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.

Interventions

2 mg KSL-W

Intervention Type: DRUG

4 mg KSL-W

Intervention Type: DRUG

6 mg KSL-W

Intervention Type: DRUG

10 mg KSL-W

Intervention Type: DRUG

20 mg KSL-W

Intervention Type: DRUG

30 mg KSL-W

Intervention Type: DRUG

50 mg KSL-W

Intervention Type: DRUG

75 mg KSL-W

Intervention Type: DRUG

100 mg KSL-W

Intervention Type: DRUG

Placebo

Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.

Intervention Type: OTHER

Other Intervention Names

Antiplaque Chewing Gum; Antiplaque Chewing Gum; Antiplaque Chewing Gum; Antiplaque Chewing Gum; Antiplaque Chewing Gum; Antiplaque Chewing Gum; Antiplaque Chewing Gum; Antiplaque Chewing Gum; Antiplaque Chewing Gum

Eligibility Criteria

Inclusion Criteria

Subjects must meet all of the following criteria to be included in the Phase 1 portion of the study:

• Males and females between 18 and 64 years of age
• A negative urine pregnancy test and willingness to use a reliable form of contraception for the duration of the study (females of childbearing potential only), with reliable contraception defined as:

Abstinence Oral contraceptive, either estrogen progesterone combined, or progesterone alone Injectable progesterone Implants of levonorgestrel Estrogenic vaginal ring Percutaneous contraceptive patches Intrauterine device or intrauterine system Double barrier method [condom or occlusive cap (diaphragm or cervical vault caps) plus spermicidal agent (foam, gel, film, cream, suppository)] Male partner sterilization prior to the female subject's entry into the study, and this male is the sole partner for that subject

• Good health, as determined by pertinent medical history, physical examination, vital signs, and clinical safety laboratory evaluations
• A minimum of 16 natural teeth with 2 scorable surfaces (facial and lingual) per tooth Sufficient number of opposing posterior teeth to chew on both sides of the mouth as determined by the examining dentist Teeth that have gross caries, full crowns or extensive restorations on facial and/or lingual surfaces, orthodontic bands, and third molars are not included in the tooth count
• Ability to comprehend and a willingness to sign an informed consent, which includes the Authorization for the Release of Health Information document
• Willingness to comply with all study procedures

Subjects must meet all the criteria for the phase 1 portion of the study, and in addition must:

• Have mild to moderate gingivitis and plaque MGI of 1.8 or greater (Ainamo and Bay-1975) PI of 1.95 or greater (Turesky et al-1970)
• Willing to forgo any optional dental procedures during the study period, such as dental prophylaxis or teeth whitening

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded from the study:

• Acute or chronic medical conditions, organ system disease, or medications that, in the principal investigator's opinion, would impair the subject's ability to participate
• TMD
• Self-reported use of tobacco products
• Use of anticoagulant medications (eg clopidogrel)
• Gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaque or calculus, or soft or hard tissue tumor of the oral cavity
• Orthodontic appliances or removable partial dentures that will compromise the ability of the potential subject to participate in the study
• Periodontitis as indicated periodontal pockets greater than 4 millimeters on more than one site
• Receipt of any investigational drug/test product within 30 days prior to study entry
• Receipt of antibiotics within 30 days prior to study entry
• Need for antibiotic prophylaxis prior to invasive dental procedures
• Receipt of daily anti-inflammatory therapy [eg nonsteroidal anti-inflammatory drugs (NSAID), tumor necrosis factor (TNF) alpha blockers] within 30 days prior to study entry
• Receipt of prescription antibacterial oral products (eg products containing chlorhexidine) within 30 days prior to study entry
• Pregnant or breast-feeding female
• Clinically significant abnormal laboratory tests as determined by the principal investigator
• An employee of the study site directly involved with the study
• Inability to comply with assigned treatment regimen

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

U.S. Army Medical Research and Development Command

FED

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Domenick T Zero, DDS, MS

Role: PRINCIPAL_INVESTIGATOR

Oral Health Research Institute, Indiana University School of Dentistry

Locations

Indiana University School of Dentistry, Oral Health Research Institute

Indianapolis, Indiana, United States

Countries

United States

References

Ryan JB, Kirkwood BJ, Leung KP. Combined Phase 1/2a Initial Clinical Safety Trials and Proof-of-Concept Assessment of a Novel Antimicrobial Peptide KSL-W Anti-Plaque Chewing Gum. Clin Exp Dent Res. 2024 Dec;10(6):e943. doi: 10.1002/cre2.943.

Reference Type: DERIVED

PMID: 39466933 (View on PubMed)

Other Identifiers

S-11-14

Identifier Type: -

Identifier Source: org_study_id